DCTs completely revise historical trial processes by executing trials through telemedicine and mobile or local health care providers. Although COVID increased the need for DCTs, 75% of the industry report very little use of decentralized and virtual trials. Read more from Dario Lirio, Senior Director, LifeSphere Clinical, over on PharmaLive.
The post The Risks and Rewards of Decentralized Clinical Trials appeared first on ArisGlobal.